Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$377.58 USD

377.58
962,429

+1.21 (0.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $377.57 -0.01 (0.00%) 6:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Zacks Equity Research

Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.

Urmimala Biswas headshot

Align Rides on Volume Expansion Amid Poor Shipment Scenario

by Urmimala Biswas

Align Technology (ALGN) is continuing with its winning streak of delivering a sturdy Invisalign Technology volume expansion across the company's entire customer base.

Zacks Equity Research

CHF Solutions System to be Used in JAHVH Study After Final Nod

by Zacks Equity Research

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.

Zacks Equity Research

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) has been consistently delivering impressive results.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock Now

by Zacks Equity Research

Investor confidence is still high on Henry Schein (HSIC), thanks to solid prospects.

Zacks Equity Research

Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes

by Zacks Equity Research

Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

Zacks Equity Research

Penumbra Enrolls First Patient for Study on Coronary Vessels

by Zacks Equity Research

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

Urmimala Biswas headshot

Thermo Fisher Gets a Boost from Buyouts and Global Expansion

by Urmimala Biswas

Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.

Zacks Equity Research

QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure

by Zacks Equity Research

If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio Now

by Zacks Equity Research

Stryker's (SYK) core Mako Platform has been consistently driving its top line.

Zacks Equity Research

Smith & Nephew's (SNN) STITCH Study Outcome Encouraging

by Zacks Equity Research

This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.

Urmimala Biswas headshot

Medtronic Submits Two Pelvic Health Devices for FDA's PMA

by Urmimala Biswas

Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

Zacks Equity Research

Omnicell Advances on Global Footing Despite Severe Rivalry

by Zacks Equity Research

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Zacks Equity Research

Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA

by Zacks Equity Research

This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock Now

by Zacks Equity Research

Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.

Zacks Equity Research

Stryker Gains From Flagship Mako and Broad Product Spectrum

by Zacks Equity Research

Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.

Zacks Equity Research

AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.

Mark Vickery headshot

Top Stock Reports for Verizon, PepsiCo & Biogen

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), PepsiCo (PEP) and Biogen (BIIB).

Zacks Equity Research

Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

by Zacks Equity Research

Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

Zacks Equity Research

Here's Why You Should Hold on to Quest Diagnostics Stock Now

by Zacks Equity Research

Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.

Zacks Equity Research

Illumina, Broad Institute Partner on Secondary Genomic Analysis

by Zacks Equity Research

The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Varian, Stryker and Medtronic

Trina Mukherjee headshot

3 MedTech Stocks in Focus on Emerging Market Prospects

by Trina Mukherjee

Emerging market countries present lucrative prospects; consequently, investors can take a look at the space.

Zacks Equity Research

Is Stryker (SYK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (SYK) Outperforming Other Medical Stocks This Year?